# SGSM2

## Overview
SGSM2, or small G protein signaling modulator 2, is a gene that encodes a protein involved in the regulation of small GTPase-mediated signaling pathways, which are essential for various cellular processes. The SGSM2 protein is a member of the SGSM1/2/3 family and is primarily associated with modulating signaling pathways involving small G proteins such as RAP1 and RAB. As a plasma membrane protein, SGSM2 plays a critical role in cell adhesion and migration by interacting with proteins like E-cadherin, which is vital for maintaining cell-cell adhesion. Additionally, SGSM2 is involved in cytoskeletal dynamics through its interactions with components like β-tubulin, influencing cell motility and structural integrity. The protein's functions are significant in both normal cellular processes and pathological conditions, such as cancer, where it has been implicated in modulating cell adhesion, migration, and signaling pathways (Su2022SGSM2; Lin2019Small).

## Function
SGSM2 (small G protein signaling modulator 2) is involved in the regulation of small GTPase-mediated signaling pathways, which are crucial for various cellular processes. In healthy human cells, SGSM2 is part of the SGSM1/2/3 protein family, known for modulating small G protein signaling pathways, including those involving RAP1 and RAB proteins (Su2022SGSM2). SGSM2 is a plasma membrane protein that plays a role in cell adhesion and migration by interacting with E-cadherin, a protein essential for cell-cell adhesion (Lin2019Small). It is implicated in maintaining cell junctions and may be involved in endocytosis processes, which are vital for cellular communication and transport (Lin2019Small).

SGSM2 also interacts with cytoskeletal components, such as β-tubulin, and is involved in cytoskeleton dynamics, which are important for cell motility and structural integrity (Lin2019Small). The protein's activity in the cytoplasm influences cellular communication and transport, impacting overall cellular function and organismal homeostasis. Although primarily studied in the context of cancer, these functions are relevant in healthy cells, particularly in processes involving cell adhesion and signaling pathways (Lin2019Small).

## Clinical Significance
Alterations in the expression of the SGSM2 gene have been implicated in the progression of certain cancers, notably thyroid cancer and breast cancer. In thyroid cancer, particularly papillary thyroid carcinoma (PTC), SGSM2 expression is significantly reduced compared to normal thyroid tissues. This reduction is associated with poor prognosis, especially in aggressive subtypes like tall-cell PTC. SGSM2 acts as a tumor suppressor in RAS wild-type thyroid cancer by inhibiting cell proliferation, migration, and invasion through the activation of RAP1, which competitively inhibits RAS activity. This leads to the downregulation of the MAPK/ERK and PI3K/AKT signaling pathways, crucial for thyroid cancer development (Su2022SGSM2).

In breast cancer, particularly estrogen receptor-positive (ER+) cases, SGSM2 is involved in enhancing migratory cell adhesion through its interaction with E-cadherin. SGSM2 expression is higher in ER+ breast cancer tissues compared to ER-negative tissues and is associated with metastasis. Alterations in SGSM2 expression can lead to changes in cell adhesion and motility, contributing to cancer progression. SGSM2's role in breast cancer is linked to its involvement in the epithelial-mesenchymal transition (EMT) process, which is characterized by increased cell motility and loss of cell-cell adhesion (Lin2019Small).

## Interactions
SGSM2 (small G protein signaling modulator 2) is known to participate in several protein interactions that are crucial for its role in cellular processes. SGSM2 interacts with E-cadherin and β-catenin, which are essential for cell-cell adhesion, particularly in the context of breast cancer metastasis. This interaction is significant during the epithelial-mesenchymal transition (EMT), a process that enhances cell motility and reduces adhesion, contributing to cancer metastasis (Lin2019Small). SGSM2 also colocalizes with phosphorylated focal adhesion kinase (phospho-FAK) at focal adhesions, which are involved in cell motility and adhesion (Lin2019Small).

In thyroid cancer, SGSM2 interacts with the small G protein Ras-associated protein 1 (RAP1), enhancing its activity. This interaction leads to the competitive inhibition of RAS activation, resulting in the downregulation of the MAPK/ERK and PI3K/Akt pathways, which are critical for cancer progression (Su2022SGSM2). SGSM2's interaction with RAP1 is confirmed through immunoprecipitation assays, highlighting its role as a tumor suppressor in thyroid cancer (Su2022SGSM2).

These interactions underscore SGSM2's involvement in modulating cell adhesion, migration, and signaling pathways, which are vital in cancer metastasis and progression.


## References


[1. (Lin2019Small) Juo-Han Lin, Wen-Jui Lee, Han-Chung Wu, Chih-Hsiung Wu, Li-Ching Chen, Chi-Cheng Huang, Hang-Lung Chang, Tzu-Chun Cheng, Hui-Wen Chang, Chi-Tang Ho, Shih-Hsin Tu, and Yuan-Soon Ho. Small g protein signalling modulator 2 (sgsm2) is involved in oestrogen receptor-positive breast cancer metastasis through enhancement of migratory cell adhesion via interaction with e-cadherin. Cell Adhesion &amp; Migration, 13(1):121–138, January 2019. URL: http://dx.doi.org/10.1080/19336918.2019.1568139, doi:10.1080/19336918.2019.1568139. This article has 5 citations.](https://doi.org/10.1080/19336918.2019.1568139)

[2. (Su2022SGSM2) Xi Su, Dong Chen, Lizhang Zhu, Hao Jia, Jiaxuan Cai, Peng Li, Bin Han, Donglai Wang, Hongtao Li, Jiaqian Fan, Mengwei Gu, Yaqi Zhou, Haixia Guan, and Wei Wei. Sgsm2 inhibits thyroid cancer progression by activating rap1 and enhancing competitive ras inhibition. Cell Death &amp; Disease, March 2022. URL: http://dx.doi.org/10.1038/s41419-022-04598-y, doi:10.1038/s41419-022-04598-y. This article has 7 citations.](https://doi.org/10.1038/s41419-022-04598-y)